Population Health Alliance (PHA) announced that Eyenuk has joined the organization as a member. Eyenuk is a global artificial intelligence (AI) medical technology and services company and a provider of real-world applications for AI Eye Screening and AI Predictive Biomarkers.
Eyenuk’s EyeArt AI system is the only FDA-cleared autonomous AI technology for detection of both more than mild and vision-threatening diabetic retinopathy.
“Population health professionals are increasingly aware of the tremendous clinical and economic value that autonomous AI technologies can bring to their organizations and patients they serve through early detection,” said Rose Maljanian, Chairman Emeritus of PHA and Chairman & CEO of HealthCAWS.
“PHA is excited about the important contribution Eyenuk can make to the population health community by bringing its technological innovation to prevent worsening complications in high volume, high risk conditions such as diabetes."
“With its potential to improve health equity and access, reduce diagnostic bias, and enable instant disease detection results at point-of-care settings, our FDA-cleared and Medicare-reimbursed EyeArt autonomous AI system is well-positioned to deliver significant clinical and economic improvements to diabetes care and population health,” said Kaushal Solanki, PhD, founder and CEO of Eyenuk.
Eyenuk will be featured during the next PHA Member Showcase Webinar on Wednesday, March 30, 2022, at 2 p.m. EDT.
During the webinar, Christy Mokrohisky, Vice President for Population Health at Providence St. Joseph Health will be the invited guest speaker and deliver a keynote presentation “Embracing Population Health Technological Innovations for Diabetes Management.”
Registration for this webinar (link) is open to all population health management professionals.